Diffuse Large B Cell Lymphoma (DLBCL)

Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Bio-CAR-T BS Study

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas

Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study

Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma

Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors

Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma

A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.

Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma